Translational Investigation nature publishing group Background: By stimulating lipofibroblast maturation, parenterally administered peroxisome proliferator-activated receptor γ (PPARγ) agonists promote lung homeostasis and injury repair in the neonatal lung. In this study, we determined whether PPARγ agonists could be delivered effectively via nebulization to neonates, and whether this approach would also protect against hyperoxia-induced lung injury. Methods: One-day old Sprague-Dawley rat pups were administered PPARγ agonists rosiglitazone (RGZ, 3 mg/kg), pioglitazone (PGZ, 3 mg/kg), or the diluent, via nebulization every 24 h; animals were exposed to 21% or 95% O 2 for up to 72 h. Twenty-four and 72 h following initial nebulization, the pups were sacrificed for lung tissue and blood collection to determine markers of lung maturation, injury repair, and RGZ and PGZ plasma levels. results: Nebulized RGZ and PGZ enhanced lung maturation in both males and females, as evidenced by the increased expression of markers of alveolar epithelial and mesenchymal maturation. This approach also protected against hyperoxiainduced lung injury, since hyperoxia-induced changes in bronchoalveolar lavage cell and protein contents and lung injury markers were all blocked by nebulized PGZ. conclusion: Nebulized PPARγ agonist administration promotes lung maturation and prevents neonatal hyperoxiainduced lung injury in both males and females. a b c d e 636
d espite several technological and therapeutic advances over the last two or three decades, bronchopulmonary dysplasia remains a significant cause of morbidity in very low birth weight infants. Bronchopulmonary dysplasia is characterized by aberrations in premature lung development following exposure to conditions such as hyperoxia, volutrauma, inflammation, and/or atelectotrauma, resulting in significantly increased prematurity-related morbidity and mortality. Therefore, attempts to advance lung maturity and develop lung-protective strategies have been the focus of research for many decades.
By stimulating alveolar interstitial lipofibroblast maturation, the nuclear transcription factor peroxisome proliferator-activated receptor γ (PPARγ) has been demonstrated to play a key role in physiologic lung development and homeostasis (1) (2) (3) . Lipofibroblasts have been demonstrated to play a central role in normal lung development by inducing alveolar epithelial-mesenchymal paracrine signaling, stimulating surfactant phospholipid and protein synthesis and by acting as endogenous antioxidants (1, 2, 4) . This is important since antenatal steroid administration, the contemporary standard intervention for enhancing fetal lung maturation, has significant limitations. For example, this therapy is effective in only 50-70% of infants, is sex-specific, has a delayed onset of action, and with repeated use, it may result in significant somatic growth restriction and neurodevelopmental handicaps (5) (6) (7) (8) . In view of the limited options for agents that can be used to stimulate lung maturation, alternate strategies for accelerating fetal lung maturation that are effective and safe are needed.
We have previously shown that the systemic administration of the PPARγ agonist rosiglitazone (RGZ), either antenatally or postnatally, enhances lung maturation and can prevent hyperoxia-induced acute neonatal lung injury without significantly affecting blood biochemical and metabolic profiles, both in the short and long terms, suggesting the therapeutic usefulness of PPARγ agonists in preventing and/or treating bronchopulmonary dysplasia (3, (9) (10) (11) (12) (13) . However, in adults, systemically administered PPARγ agonists are known to be associated with significant side effects (14) (15) (16) . Here, we determined whether PPARγ agonists could be delivered effectively via nebulization, and whether this would afford protection against hyperoxiainduced neonatal lung injury. Though we have previously used RGZ to study the effects of the PPARγ agonist class of agents on lung maturation, in this study, we also included pioglitazone (PGZ) because of its superior safety profile in adults when compared to RGZ (17, 18) . Hypothesizing that PPARγ agonists given via nebulization would enhance lung maturation and block hyperoxia-induced lung injury, using a rat model, in this study, we determined whether the nebulized PPARγ agonists RGZ or PGZ stimulate lung maturation, protect against hyperoxia-induced acute neonatal lung injury, and affect extra-pulmonary PPARγ-expressing organs. Lung maturation was assessed by determining the expression of key alveolar epithelial and mesenchymal molecular markers that are the hallmarks for the functional maturation of the developing 
Nebulized PPARγ agonists for neonates
Articles lung, including expression of surfactant proteins (SPs) B and C, choline incorporation into saturated phosphatidylcholine, and triolein uptake by the lung. To assess lung injury, in addition to these markers of lung maturation, lung morphometry, lung apoptosis, important intermediates of transforming growth factor β (TGF-β) activation and lung vascular markers (vascular endothelial-derived growth factor and platelet endothelial cell adhesion molecule-1), lung cytokines (IL-6, IL-1β, chemokine ligand 2, and macrophage migration inhibitory factor), and bronchoalveolar lavage (BAL) fluid protein and cellular contents were analyzed. As proof-of-principle for possible systemic effects of nebulized PPARγ, plasma levels of RGZ and PGZ, and PPARγ receptor expression in liver, heart, and kidney were determined (PPARγ is expressed in a wide range of tissues such as, but not limited to, adipose tissue, heart, brain, skeletal muscle, liver, intestine, kidney, pancreas, and spleen).
RESULTS

Effect of Nebulized RGZ and PGZ on Alveolar Differentiation Markers
Twenty-four hours following nebulization, compared to the controls, RGZ and PGZ increased the expression of lung epithelial differentiation markers (SPB and SPC) in both females and males (Figure 1a) , though there were no differences in response between the two genders. Since our laboratory has previously shown that mesenchymal PPARγ signaling is key to alveolar differentiation, we determined the effects of nebulized PGZ and RGZ on PPARγ and its down-stream targets adipocyte differentiation-related protein (ADRP) and leptin. Twenty-four hours following nebulization, the expression of these markers was significantly increased in both females (PPARγ, ADRP, and leptin, with both PGZ and RGZ), and males (PPARγ, ADRP, and leptin with PGZ, and PPARγ and ADRP with RGZ) (Figure 1b) . The effects of nebulized PGZ and RGZ on overall alveolar maturation are also reflected by functional alveolar markers such as a significantly increased rate of [ 3 H] choline incorporation into saturated phosphatidylcholine (Figure 1c) , and increased rates of triolein uptake (Figure 1d ) in response to both PGZ and RGZ.
Gender-Specific Effects of RGZ and PGZ Nebulization on Markers of Alveolar Maturation
At the 24 h time point, there were no major differences in increases in epithelial (Figure 2a ) and mesenchymal (Figure 2b ) markers of alveolar maturation in males vs. females following exposure to nebulized RGZ or PGZ. Similarly, there were no significant differences in male and female responses for the markers of overall alveolar maturation; hence, the combined gender data for [ 3 H] choline incorporation into saturated phosphatidylcholine and [ 3 H] triolein uptake are shown in Figure 1c ,d.
Plasma Levels of RGZ and PGZ Following Nebulization
Pioglitazone (0.83 ± 0.26 mg/ml (males); 0.99 ± 0.21 (females)) and RGZ (0.2 ± 0.075 (male); 0.4 ± 0.08 mg/ml (female)) were detectable in the plasma of males and females, 24 h after nebulization. Though female RGZ plasma levels were significantly higher than in males, there were no statistically significant differences in PGZ plasma levels between the males and females. At the 72 h time point, the plasma PGZ level for the combined gender group was 0.52 ± 0.15 µg/ml. As expected, PGZ and RGZ levels were undetectable in plasma samples from control groups.
Effects of Nebulized RGZ and PGZ on Extrapulmonary PPARγ-Expressing Organs
To assess the effects of nebulized RGZ and PGZ on extrapulmonary PPARγ-expressing organs such as the liver, heart, and kidney, 24 h after nebulization, PPARγ protein levels in these tissues were determined. Only in the livers of the PGZ nebulized animals (both females and males) were the PPARγ protein levels significantly increased, while there were no significant effects on PPARγ protein levels in the hearts and kidneys of either the PGZ or RGZ nebulized animals (data not shown).
Having demonstrated that nebulized RGZ and PGZ administration enhanced neonatal rat lung maturation, we next examined whether nebulized PGZ provided any protection against hyperoxia-induced neonatal lung injury. For this, we administered nebulized PGZ once daily (q 24 h), starting on day 1 of life, for up to 72 h, and exposed the pups to either normoxia or hyperoxia (95% O 2 ) during the experimental period.
Effects of Nebulized PGZ on Hyperoxia-Induced Neonatal Lung Injury
Compared to the controls, the BAL total cell count (Figure 3a (Figure 4d ) protein levels in the hyperoxiaexposed group (P < 0.05 vs. control); all of these changes were blocked in the PGZ nebulized group. Hyperoxia-induced decreases in vascular markers such as vascular endothelialderived growth factor (Figure 5a ) and platelet endothelial cell adhesion molecule-1 (Figure 5b) were blocked with PGZ nebulization. Similarly, hyperoxia-induced alterations in the lung cytokine (IL-6, IL-1β, chemokine ligand 2, and macrophage migration inhibitory factor) profile were blocked in the PGZ nebulized group (Figure 6a-d) . Hyperoxia-induced lung injury, as reflected by the decreased BcL2/Bax protein ratio, was also blocked by PGZ nebulization (Figure 6e ). In line with these data, and perhaps even more importantly, hyperoxiainduced lung morphometric changes, as determined by radial alveolar count and mean linear intercept, were also blocked in the PGZ nebulized group (Figure 7) . To compare the efficacy of protection against hyperoxia-induced neonatal lung injury, using nebulized PGZ (1 mg/kg body weight) vs. that afforded by the intraperitoneally administered PGZ (3 mg/kg body weight), alterations in select injury repair markers (PPARγ, ADRP, BcL2, and fibronectin) were determined. There was equally effective protection in hyperoxia-induced alterations in these markers using the lower nebulized dose vs. the higher intraperitoneally administered dose (Figure 8) .
Lastly, since hyperoxia-induced neonatal lung injury is known to be mediated via TGF-β activation (9,10), we next determined the effect of nebulized PGZ on hyperoxia-induced Articles Morales et al.
alterations in key intermediates of TGF-β activation. As expected, p-Smad3, Smad7, and ALK-5 (TGF-β II receptor) protein levels were significantly increased in the hyperoxia exposure group, with blockade of this response in the PGZnebulized group (Figure 9 ).
DISCUSSION
In this study, we demonstrate that the PPARγ agonists RGZ and PGZ, given via nebulization to newborn Sprague Dawley rat pups result in enhanced lung maturation, in both male and female neonatal rat pups equally, as evidenced by the increased expression of alveolar epithelial (SPB, SPC, and surfactant phospholipid synthesis) and mesenchymal (PPARγ, ADRP, and leptin protein levels, and triolein uptake) maturation markers. Furthermore, the nebulized PPARγ approach also protected against hyperoxia-induced neonatal lung injury, since hyperoxia-induced changes in BAL cell and protein contents, lung tissue maturation and injury markers (BcL2, Bax, and TGF-β activation markers) were all blocked by nebulized PGZ. In general the effects of nebulized RGZ or PGZ (3 mg/kg) on alveolar mesenchymal and epithelial differentiation markers seem to be similar to the previously reported effects following intraperitoneal administration of RGZ at a comparable dose (3); however, at a lower dose (1 mg/kg body weight), nebulized PGZ, seems to be equally effective in preventing hyperoxia-induced neonatal lung injury compared to the protection afforded with a relatively higher parenterally-administered dose (3 mg/kg body weight). Therefore, it seems that administration of nebulized PPARγ agonists represents an effective strategy for enhancing postnatal lung maturation, preventing neonatal hyperoxia-induced lung injury in both males and females.
Since, pulmonary immaturity is the main contributor to the morbidity and mortality of premature infants (19) , it is of great relevance to determine novel and safer agents to stimulate lung maturation, acting in a nongender discriminatory manner. Other than antenatal steroids, no intervention has proven effective in enhancing lung maturation, let alone preventing 
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Articles hyperoxia-induced lung damage (5, 20) . A number of recent studies have suggested PPARγ agonists as potential lung maturation and protection agents (3, (9) (10) (11) (12) (21) (22) (23) . The prior work on the use of PPARγ agonists to enhance lung maturation has also shown that both antenatal and postnatal intraperitoneal RGZ administration block hyperoxia-induced lung molecular and morphometric changes postnatally (9, 10) . Therefore, it should not be surprising that in line with the previous work, nebulized PGZ stimulated alveolar maturation and protection against hyperoxia-induced neonatal lung injury, since lipofibroblast differentiation is driven by PPARγ, and since lipofibroblasts are known to be cytoprotective against oxidant injury, and produce specific growth and differentiation and homeostasis (1, 4, 24) . However, in adults the chronic use of PPARγ agonists has been shown to be associated with significant side effects, e.g., cardiovascular effects with RGZ, and bladder cancer with PGZ (14) (15) (16) (17) 25) . In line with our prior studies, where we have shown that RGZ given parenterally, either antenatally or postnatally, doesn't affect either cardiac troponin or any of the other metabolic parameters examined, such as the blood lipid profile and glucose and insulin tolerance tests (3, (11) (12) (13) , in this study too, plasma cardiac troponin levels were undetectable in both control and hyperoxia-exposed animals with or without PGZ treatment.
We found that even when given via nebulization, both RGZ and PGZ seem to be systemically absorbed, as reflected by detectable plasma levels. However, other than the increase in the PPARγ protein levels in the livers of PGZ and RGZ nebulized animals, there seem to be no effects on either PPARγ or its downstream targets, such as ADRP and leptin protein levels (data not shown), in any other PPARγ-expressing extra-pulmonary organs such as the heart and kidney, by either RGZ or PGZ.
In summary, treatment with nebulized PPARγ agonist accelerated neonatal lung maturation and prevented hyperoxiainduced lung injury, representing an effective and potentially safe therapeutic strategy. Though more work needs to be done to establish the safety profile and effective clinical use in neonates, the work presented here provides further proof-ofprinciple for the beneficial effects of this class of drugs in the prevention and management of neonatal lung injury.
METHODS
Animal Protocol
Pathogen-free, time-mated Sprague-Dawley rat dams were obtained from Charles River Laboratories (Hollister, CA) at day 16 of gestation, acclimatized in humidity-and temperature-controlled rooms with 12-h light and dark cycles, and provided food and water ad libitum. On day 22 of pregnancy the dams delivered spontaneously. One-day-old rat pups breastfed ad libitum were used and were grouped into nebulizing groups (using a Lincare Nebulizer, PariRespiratory Equipment, Midlothian, VA) as follows: One set of pups was maintained in room air and exposed to either nebulized 1 ml normal saline containing the diluent dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St Louis, MO) (60 μl) and another set exposed to nebulized RGZ (Cayman Chemicals, Ann Arbor, MI) or PGZ (Cayman Chemicals) (3 mg/kg in 60 μl DMSO, diluted in 1 ml saline), nebulized over 30 min, in an enclosed chamber (28 × 17 × 12 cm). Twenty-four hour later pups were sacrificed for tissue and blood collection. For assessing the protection against hyperoxia-induced neonatal lung injury by using nebulized PPARγ agonist administration, some control animals were maintained in room air and nebulized with 1 ml normal saline (containing the diluent DMSO), while the hyperoxia (95% O 2 ) exposure group animals were treated with either 1 ml nebulized saline (containing the diluent DMSO) or nebulized PGZ (3 mg/kg in 60 µl DMSO, diluted in 1 ml saline), respectively, every 24 h for up to 72 h. Continuous 95% Articles Morales et al. O 2 exposure was achieved in a plexiglass chamber (77 × 64 × 37 cm) using a flow-through system. For monitoring of oxygen levels inside the chamber, a Ceramatec (MAXO 2 ) oxygen analyzer (Maxtec, Salt Lake City, UT) was used. In yet another subset of animals, efficacy for protection against hyperoxia-induced lung injury using nebulized PGZ (1 mg/kg body weight) administration was compared with the parenteral (intraperitoneal) PGZ (3 mg/kg body weight) administration. After the experimental period, the pups were sacrificed using 0.1 ml euthasol (sodium pentobarbital 390 mg + sodium phenytoin 50 mg/ml; Virbac, Fort Worth, TX) per pup. To determine the effects 
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Articles of RGZ or PGZ on extrapulmonary PPARγ-expressing organs, heart, liver and kidney tissue was flash-frozen upon retrieval from the sacrificed animals. Blood was collected by cardiac puncture from each pup and frozen at −80 °C for subsequent determination of plasma RGZ and PGZ levels. The lungs were collected and processed either immediately for [ 3 H] choline incorporation and [ 3 H] triolein uptake studies, or flash-frozen for later Western hybridization for the markers of lung maturation. All animal procedures were performed following the guidelines of the National Institutes of Health (Bethesda, MD) for the care and use of laboratory animals, and approved by the Los Angeles Biomedical Research Institute, Animal Care and Use Committee.
BAL Collection
Pups were euthanized using pentobarbital (100 mg/kg i.p.), and a 27-gauge angiocatheter was ligated in place for BAL collection. Two 0.5-ml BALs were slowly performed by instilling 0.5 ml phosphatebuffered saline + 5 mmol/l ethylenediamine tetra-acetate. Retrieved solutions were pooled and centrifuged at 400g for 10 min. Sediments were analyzed for total cell counts and supernatants were snap-frozen in liquid nitrogen and subsequent analysis. 
Protein Extraction and Western Blot Analysis
Measurement of Rate of Surfactant Phospholipid Synthesis
De novo surfactant phospholipid synthesis, triglyceride uptake and incorporation of [methyl-3 H]-choline chloride (NEN Dupont, Boston, MA) into saturated phosphatidylcholine in cultured lung explants were determined as described previously (13) .
Lung Morphometry
Lung morphometry was performed as described previously (3, 10) .
Immunofluorescence Staining
For immunofluorescence staining, rat lungs were inflated in situ with 4% paraformaldehyde in phosphate buffer at a standard inflation pressure of 5 cm H 2 O for 4 h at 4 °C. The lungs were subsequently transferred to phosphate-buffered saline containing 30% sucrose (wt/vol) until equilibrated in the cold (4 °C). After fixation, 5-μm paraffin sections were treated three times with Histo-Clear (National Diagnostics, Atlanta, GA) for 5 min, and then rehydrated by a sequential ethanol wash. Sections were then washed twice for 10 min with phosphatebuffered saline, and blocked for 1 h in phosphate-buffered saline-5% normal goat serum-0.2% Triton X-100. Sections were incubated with primary antibodies for 1 h at room temperature, and then with the appropriate secondary antibody for 1 h, also at room temperature. Antibodies used included platelet endothelial cell adhesion molecule (primary antibody, 1:10, BD Biosciences, San Jose, CA); secondary antibody, 1:100, Alexa Fluor, anti-rabbit 568 red); BCL-2 (primary antibody, 1:100, Santa Cruz, Santa Cruz, CA; secondary antibody, 1:100, Alexa Fluor, anti-rabbit 488 green); Bax (primary antibody, 1:100, Santa Cruz; secondary antibody, 1:100, Alexa Fluor, anti-rabbit 568 red). The sections were washed with phosphate buffered saline and then mounted with ProLong Gold antifade reagent with DAPI (Invitrogen) for visualization under a fluorescence microscope.
Real Time RT-PCR
For lung cytokine assay, RNA extraction and q-RT-PCR was performed according to previously described methods (26) . RT-PCR primers used included IL6: F5′-CTTCCTACCCCAACTTCCAA-3′ and R5′-ACCACAGTGAGGAATGTCCA-3′ (191 bp); IL-1β: F5′-AGA GTGTGGATCCCAAACAA-3′ and R5′-AGTCAACTATGTCCCGA CCA-3′ (186 bp); chemokine ligand 2: F5′-TTGTCACCAAGCTCAA GAGA-3′ and R5′-GGTTGTGGAAAAGAGAGTGG-3′ (206 bp); and macrophage migration inhibitory factor: F5′-AGAACCG CAACTACAGCAAG-3′ and R5′-ACGGGTGGATAAACACAGAA-3′ (208 bp). The normalization control was 18S ribosomal RNA. Data were analyzed using a threshold level of fluorescence that was in the linear range of the PCR reaction. The CT value for 18S ribosomal RNA was subtracted from the CT value for the gene of interest to obtain a delta CT (∆CT) value. The relative fold-change for each gene was calculated using the ∆∆CT method. Results were expressed as the mean ± SE, and considered statistically significant at P < 0.05.
Measurement of RGZ and PGZ in Plasma and Lungs
RGZ and PGZ were measured by a high-performance liquid chromatography (HPLC) gradient program using a 50:50 (or 1:1) mixture of acetonitrile and methanol (solvent A), and 50 mmol/l ammonium acetate buffer, pH 8.0 (solvent B). The HPLC column was a Whatman mBondapak C 18 analytic column (3.6 × 150 mm). Elution of RGZ and PGZ was accomplished with a timed gradient program beginning with 100% solvent B, 5 min; then changed to 50% solvent B for 20 min; followed by 95% solvent B for 5 min and held for 10 min at this percentage of 95% solvent B. RGZ and PGZ had retention times of 29 ± 0.5 min, and 15 ± 0.5 min, respectively, and the amounts of RGZ and PGZ were calculated from a standard curve for pure RGZ run in tandem for each assay.
Measurement of Plasma Cardiac Troponin I Levels
Plasma cardiac troponin I levels were determined by a rat cardiac Tn-I ELISA kit as per the manufacturer's protocol (Life Diagnostics, West Chester, PA) (detection limit of 0.156 ng/ml, and 100% specificity).
Statistical Analysis
The experiments were done at least three independent times. The experimental data was analyzed using one-way analysis of variance, with Tukey's post hoc analysis as appropriate. The results are expressed as means ± SD. P value of <0.05 was considered to represent statistically significant differences between the groups.
